ANDA 76266, held by Chartwell Injectable. Doxapram Hydrochloride.
As of Nov 16, 2026, ANDA 76266 (Doxapram Hydrochloride), held by Chartwell Injectable, was first approved by FDA on Jan 10, 2003, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jan 10, 2003 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Doxapram Hydrochloride20MG/ML ยท injectable;injection | Doxapram Hydrochloride | Rx |
| May 29, 2007 | Supplement 2Labeling | Approved | None posted |
| Jan 10, 2003 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters